S&P Futures
4,269.25 -7.50 (-0.18%) Dow Futures
33,923.00 -40.00 (-0.12%) Nasdaq Futures
13,459.50 -33.75 (-0.25%) Russell 2000 Futures
1,988.20 -0.90 (-0.05%) Crude Oil
88.05 -0.06 (-0.07%) Gold
1,779.40 +2.70 (+0.15%)
SciSparc Ltd. (SPRC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.9400 |
| Open | 0.9600 |
| Bid | 0.9300 x 1000 |
| Ask | 0.9250 x 800 |
| Day's Range | 0.8800 - 1.0700 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 999,373 |
| Market Cap | 2.157M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4230 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories TEL AVIV, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has signed a non-binding let
- GlobeNewswire
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has been granted an Israeli patent for its core technology that treats central nervous systems disorders. The
- GlobeNewswire
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD TEL AVIV, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has received approval from the Israeli Ministry of Health to conduct the Company’s clinical
